Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study

NCT06596746 is registered in ClinicalTrials.gov with Casa di Cura San Raffaele Cassino as lead sponsor.

NCT NCT06596746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06596746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study
Lead sponsor
Casa di Cura San Raffaele Cassino
Phase
Observational
Overall status
Recruiting
Start date
September 9, 2024
Completion date
September 9, 2034
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, amyotrophic lateral sclerosis, atypical parkinsonism, cognitive impairment, corticobasal degeneration, dementia, frontotemporal lobar degeneration, iron overload, lewy body disease, movement disorders, multiple system atrophy, neurodegeneration with brain iron accumulation (nbia), neurodegenerative diseases, parkinson disease, supranuclear palsy, progressive, synucleinopathies, tauopathies, tdp-43 proteinopathies